2024 SABCS Meeting Magazine - 27

SESSIONS OF NOTE
" Sometimes, screening
may result in the detection
of lesions that pose no
threat to life and would
never have been detected
in the absence of screening,
so overdiagnosis may result
in unnecessary treatments
(overtreatment), " Dr. Jatoi
said, calling overdiagnosis
a major public health issue
that needs to be addressed.
Currently, novel
breast cancer screening
strategies are often
implemented if
they are shown
to improve tumor
detection rates, but
Dr. Jatoi notes that
tumor detection
has not been
validated
as a proper
surrogate
outcome
measure for
mortality. He
advocates
moving away
from tumor
detection as
a surrogate
endpoint
in cancer
screening
trials.
" We need to find better
endpoints that are proper
surrogates for mortality
and proper surrogates for
improved quality of life, " Dr.
Jatoi said, adding that he
hopes this will be part of
the discussion at the 2024
SABCS®.
" The underlying question
" We don't need
to focus our efforts
on finding disease
as early as possible,
but rather as early
as needed to have a
beneficial effect on
mortality. "
Ismail Jatoi, MD
surrounding this whole
issue should not be about
early detection in and of
itself, " Dr. Jatoi continued.
" Early detection is closely
intertwined with early
treatment, so
there is a strong
treatment
interaction
associated with
cancer screening.
Given the
nuances
of early
detection,
striving for
optimal
timing of
treatment for
maximum
efficacy
remains the
priority.
" Ultimately,
the goal of
screening
and early
detection is to reduce
mortality and improve quality
of life, " Dr. Jatoi said. 
December 10-13, 2024 | San Antonio, Texas
The Risk Reduction and Early Detection
track is a new addition to the 2024
SABCS® program and an opportunity for
attendees to deepen their knowledge
about these vital topics.
* Tuesday, Dec. 10, 12:00 - 1:45 p.m.
Risk Reduction and Early Detection:
Mechanisms of Obesity Related Risk for
Breast Cancer and Approaches to Risk
Reduction
* Lifestyle, Genetic, and Epigenetic
Interactions in Predicting Development
of Obesity and Response to Calorie
Restriction and Physical Activity
* Achieving Sufficient Fat Loss and Metabolic
Improvement to Reduce Cancer Risk:
Newer Generation GLP-1n and GIP Receptor
Agonists (NUSH-Based Therapeutics)
* Impact and Types of Exercise and
Pharmacotherapy in Weight Loss
* Wednesday, Dec. 11, 12:00 - 1:45 p.m.
Risk Reduction and Early Detection:
Updates on Breast Cancer Screening
* Risk-Based Screening in the Average
Population
* Novel Imaging Modalities
* Screening for High-Risk Women
* Thursday, Dec. 12, 12:30 - 1:45 p.m.
Risk Reduction and Early Detection: The
Future of Cancer Genetics Is Here
* Saturation Genome Editing-Based Functional
and Clinical Classification of VUS in BRCA2
* Updates on Risk Prediction Models
* Reversion Mutations in BRCA1/2 in
Response to Therapy
* Friday, Dec. 13, 12:30 - 1:45 p.m.
Risk Reduction and Early Detection: New
Directions in Breast Cancer Prevention
* Prevention Vaccines: Where Are We Now
and Where Are We Going?
* Can We Use Biomarkers to Implement
Prevention?
* From Bench to Clinical Trial: A New Target
for Breast Cancer Prevention
ALL LISTED TIMES ARE IN CT. SEE PAGES
8-15 FOR FULL SESSION DETAILS.
27
2024 SABCS Meeting Magazine

Table of Contents for the Digital Edition of 2024 SABCS Meeting Magazine
